Nanoscope Therapeutics Announces FDA Clearance of IND for MCO-010 Gene Therapy in Stargardt Macular Degeneration Patients
BEDFORD, Texas, Jan. 25, 2022 -- (Healthcare Sales & Marketing Network) -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced it received IND clearance from the ... Regenerative Medicine, Ophthalmology, FDA Nanoscope Therapeutics, Stargardt, optogenetic, gene therapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Gene Therapy | Genetics | Marketing | Nanotechnology | Opthalmology | Pharmaceuticals | Vitamin A